Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 4Withdrawn 2Unknown 2Terminated 2Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 17Breast 17Sarcoma 6Other hematologic neoplasm 6Gastrointestinal 5Gynecologic 4Plasma cell 2Myeloid 2Tumor-Agnostic 1Genitourinary 1Dermatologic 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Blast Crisis 1

Interventions

Cyclophosphamide 14fludarabine phosphate 9Peripheral Blood Stem Cell Transplantation 9fludarabine 8Cytarabine 8Busulfan 8Azacitidine 8Whole-Body Irradiation 7Methotrexate 7Cyclosporine 6Tacrolimus 5Filgrastim 5Decitabine 5nilotinib 4Mycophenolic Acid 4Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Dasatinib 3Biopsy 3AP 1903 reagent 3venetoclax 2sabatolimab 2ruxolitinib 2merphos 2magrolimab 2ivosidenib 2decitabine and cedazuridine drug combination 2Stem Cell Transplantation 2Specimen Handling 2Sirolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Doxorubicin × Myeloid × Clear all
NCT03059615 2020-07-31

A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS

Immune System Key Ltd

Phase 2 Withdrawn
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01670084 2015-10-30

Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia

Mayo Clinic

Phase 2 Withdrawn
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡